Basic Pharmacology Midterm Quiz PDF
Document Details
Uploaded by HappierBixbite
Delta University For Science And Technology
2023
Delta University
Tags
Summary
This is a midterm quiz from the Department of Pharmacology and Biochemistry at Delta University, focusing on drug effects, responses, metabolism, and related concepts.
Full Transcript
Name:........................................ ID:..................... (Question 1) 5. Which of the following is a common Phase I reaction that involves adding an oxygen atom to the dr...
Name:........................................ ID:..................... (Question 1) 5. Which of the following is a common Phase I reaction that involves adding an oxygen atom to the drug Choose the correct answer, write your molecule? answers in the pubble sheet. Hydrolysis 1. Regarding drug effect, the drug which has no efficacy is Reduction termed Oxidation Full agonist Dealkylation Partial agonist 6. Which phase of drug metabolism is focused on making Antagonist drugs more polar and water-soluble? None of the above Phase I 2. The EC50 is Phase II The amount of drug, which produces the Phase III maximal therapeutic response Both phase I and phase II The amount of drug which produces half the 7. The TD50 is maximal therapeutic response The amount of drug, which produces the The ability of the drug receptor complex to maximal therapeutic response produce the maximal response The amount of drug which produces half the The amount of drug which produces toxic maximal therapeutic response effects in half the population The ability of the drug receptor complex to 3. The higher the Emax, produce the maximal response The higher the potency of the drug The amount of drug which produces toxic The lower the potency of the drug effects in half the population The higher the efficacy of the drug 8. The higher the EC50, The lower the efficacy of the drug The higher the potency of the drug 4. The therapeutic index is a measure for ……….. of the The lower the potency of the drug drug The higher the efficacy of the drug The potency The lower the efficacy of the drug The safety The affinity The efficacy page 1 9. The antagonist is termed ……., when it replaces the (Question 2) agonist at its binding site at the receptor. Answer the following questions. Non-competitive Functional Competitive None of the above 10. Antacids can exert their actions through Non-receptor mediated action Receptor mediated action Both receptor & non-receptor mediated actions None of the above mechanisms 11. If the ED50 of drug A is 10 mg, and the TD50 is 50 mg, The following figure represents the bioavailability of while the ED50 of drug B is 20 mg, and the TD50 is 60 different formulations (A, B, and C) that contain the same mg, then active gradient. Drug A is more potent & safer than Drug B 1. Which formulation reaches the most optimum Drug A is more potent & less safe than Drug B plasma concentration? Drug A is less potent, & safer than Drug B Which formulation has the longest duration of Drug A is less potent, & less safe than Drug B 12. The Drug that has affinity to the receptor, and intrinsic action? activity > zero, is termed Which formulation has the highest Full agonist toxicity? Partial agonist Which formulation has the highest elimination Competitive antagonist rate? Allosteric antagonist 2. Explain why the onset of action A is more than B. 13. What is the primary goal of Phase II metabolism? Make drugs less polar Make drugs more toxic Make drugs less reactive 3. Due to the increased binding affinity of sulphonamides Make drugs more water-soluble to plasma protein, they have lower distribution, 14. Why should drugs that cross the placenta be avoided (Explain). during pregnancy? To increase the fetus's tolerance to drugs To enhance the mother's drug metabolism 4. Enumerate factors that allow polar drugs to cross BBB To reduce drug interactions To avoid harmful effects on the fetus 15. Which drugs can pass through capillaries and enter 5. The dose of warfarin should be increased after interstitial fluid? administration of phenobarbitone, the LME inducer. Water-soluble drugs Non-polar drugs Low molecular weight drugs High molecular weight drugs page 2